ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the developmentMOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Author: AI Journal

Source: AI Journal

2026/02/23 21:48

2 min read

CHAT$0.0554+0.54%

MOUNTAIN$0.0000572-21.10%

INC$0.4989+0.64%

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

TD Cowen 46^th Annual Healthcare Conference, March 2-5, 2026
- Format: Fireside chat and one-on-one meetings
- Presentation Date & Time: March 3, 2026, 1:50 pm EST
- Location: Boston, MA

Jefferies 2026 Biotech on the Beach Summit, March 10-11, 2026
- Format: One-on-one investor meetings
- Location: Miami, FL

Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

Contacts

Investor & Media Contact:
Nick Smith
investors@altoneuroscience.com

Market Opportunity

Solchat Price(CHAT)

$0.0554

$0.0554$0.0554

+2.40%

USD

Solchat (CHAT) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.